Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Hemorrhagic Disorders

ClinicalTrials.gov lists 6,374 trials for Hemorrhagic Disorders or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 192.

MeSH D006474 Hemic and Lymphatic Diseases C15
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 1,139 Phase 1/2 Phase 1/2 606 Phase 2 Phase 2 1,545 Phase 2/3 Phase 2/3 75 Phase 3 Phase 3 740 Phase 4 Phase 4 206 Not applicable Not applicable 665 Observational Observational 1,357 Phase 1 Phase 1 1,139 Phase 1/2 Phase 1/2 606 Phase 2 Phase 2 1,545 Phase 2/3 Phase 2/3 75 Phase 3 Phase 3 740 Phase 4 Phase 4 206 Not applicable Not applicable 665 Observational Observational 1,357

Trials per phase (log scale)

2 more sections with rows

63 of the 6,374 trials are tagged with Hemorrhagic Disorders itself; the rest are tagged with a narrower condition beneath it.

Get the Hemorrhagic Disorders report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Hemorrhagic Disorders trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 24 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 350

1990: 2 trials (Observational 1, Phase 2 1) 1991: 1 trials (Phase 2 1) 1992: 5 trials (Phase 2 2, Phase 1/2 2, Phase 1 1) 1993: 7 trials (Observational 2, Phase 3 1, Phase 2 3, Phase 1 1) 1994: 7 trials (Not applicable 1, Phase 3 3, Phase 2 3) 1995: 15 trials (Observational 4, Phase 3 4, Phase 2 5, Phase 1/2 1, Phase 1 1) 1996: 18 trials (Observational 2, Phase 3 5, Phase 2 9, Phase 1 2) 1997: 32 trials (Observational 1, Not applicable 3, Phase 4 1, Phase 3 7, Phase 2 13, Phase 1/2 2, Phase 1 5) 1998: 55 trials (Observational 2, Not applicable 2, Phase 4 1, Phase 3 6, Phase 2/3 1, Phase 2 32, Phase 1/2 2, Phase 1 9) 1999: 55 trials (Observational 2, Not applicable 4, Phase 3 8, Phase 2 25, Phase 1/2 5, Phase 1 11) 2000: 72 trials (Observational 6, Not applicable 9, Phase 4 1, Phase 3 15, Phase 2/3 1, Phase 2 26, Phase 1/2 9, Phase 1 5) 2001: 66 trials (Observational 4, Not applicable 8, Phase 4 3, Phase 3 10, Phase 2/3 4, Phase 2 23, Phase 1/2 6, Phase 1 8) 2002: 96 trials (Observational 13, Not applicable 6, Phase 3 16, Phase 2/3 2, Phase 2 35, Phase 1/2 12, Phase 1 12) 2003: 91 trials (Observational 6, Not applicable 11, Phase 4 5, Phase 3 18, Phase 2/3 2, Phase 2 21, Phase 1/2 11, Phase 1 17) 2004: 121 trials (Observational 12, Not applicable 8, Phase 4 3, Phase 3 15, Phase 2/3 3, Phase 2 48, Phase 1/2 14, Phase 1 18) 2005: 157 trials (Observational 17, Not applicable 11, Phase 4 4, Phase 3 22, Phase 2 57, Phase 1/2 16, Phase 1 30) 2006: 164 trials (Observational 20, Not applicable 9, Phase 4 8, Phase 3 29, Phase 2/3 1, Phase 2 56, Phase 1/2 17, Phase 1 24) 2007: 175 trials (Other 1, Observational 22, Not applicable 9, Phase 4 4, Phase 3 19, Phase 2/3 1, Phase 2 63, Phase 1/2 21, Phase 1 35) 2008: 211 trials (Observational 39, Not applicable 7, Phase 4 5, Phase 3 23, Phase 2/3 4, Phase 2 64, Phase 1/2 20, Phase 1 49) 2009: 186 trials (Other 2, Observational 29, Not applicable 11, Phase 4 8, Phase 3 30, Phase 2/3 6, Phase 2 49, Phase 1/2 20, Phase 1 31) 2010: 230 trials (Observational 45, Not applicable 17, Phase 4 10, Phase 3 25, Phase 2/3 1, Phase 2 63, Phase 1/2 28, Phase 1 41) 2011: 207 trials (Observational 43, Not applicable 14, Phase 4 5, Phase 3 33, Phase 2/3 2, Phase 2 47, Phase 1/2 28, Phase 1 35) 2012: 224 trials (Observational 36, Not applicable 17, Phase 4 5, Phase 3 31, Phase 2/3 4, Phase 2 62, Phase 1/2 20, Phase 1 49) 2013: 183 trials (Observational 33, Not applicable 15, Phase 4 5, Phase 3 26, Phase 2/3 4, Phase 2 44, Phase 1/2 26, Phase 1 30) 2014: 248 trials (Observational 53, Not applicable 17, Phase 4 9, Phase 3 31, Phase 2/3 3, Phase 2 51, Phase 1/2 26, Phase 1 58) 2015: 260 trials (Observational 71, Not applicable 20, Phase 4 10, Phase 3 24, Phase 2/3 2, Phase 2 68, Phase 1/2 21, Phase 1 44) 2016: 234 trials (Observational 63, Not applicable 22, Phase 4 8, Phase 3 25, Phase 2/3 2, Phase 2 62, Phase 1/2 19, Phase 1 33) 2017: 270 trials (Observational 70, Not applicable 23, Phase 4 10, Phase 3 29, Phase 2/3 2, Phase 2 59, Phase 1/2 27, Phase 1 50) 2018: 286 trials (Observational 84, Not applicable 32, Phase 4 6, Phase 3 23, Phase 2/3 4, Phase 2 69, Phase 1/2 24, Phase 1 44) 2019: 306 trials (Observational 80, Not applicable 30, Phase 4 13, Phase 3 30, Phase 2/3 1, Phase 2 58, Phase 1/2 36, Phase 1 58) 2020: 309 trials (Observational 93, Not applicable 49, Phase 4 12, Phase 3 33, Phase 2/3 3, Phase 2 55, Phase 1/2 14, Phase 1 50) 2021: 350 trials (Observational 84, Not applicable 45, Phase 4 9, Phase 3 31, Phase 2/3 4, Phase 2 73, Phase 1/2 29, Phase 1 75) 2022: 341 trials (Observational 92, Not applicable 43, Phase 4 21, Phase 3 33, Phase 2 63, Phase 1/2 30, Phase 1 59) 2023: 330 trials (Observational 85, Not applicable 55, Phase 4 8, Phase 3 26, Phase 2/3 4, Phase 2 62, Phase 1/2 39, Phase 1 51) 2024: 316 trials (Observational 87, Not applicable 54, Phase 4 7, Phase 3 29, Phase 2/3 1, Phase 2 46, Phase 1/2 23, Phase 1 69) 2025: 322 trials (Observational 79, Not applicable 51, Phase 4 13, Phase 3 32, Phase 2/3 6, Phase 2 59, Phase 1/2 25, Phase 1 57)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 323
2025 322
2024 316
2023 330
2022 341
2021 350
2020 309
2019 306
2018 286
2017 270

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 360 trials starting in 2026 and about 340 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 714 trials still running at the 2026-10-09 snapshot; registered median of 35 months across 3,903 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Hemorrhagic Disorders trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 1,139
Phase 1/2 606
Phase 2 1,545
Phase 2/3 75
Phase 3 740
Phase 4 206
Not applicable 665
Observational 1,357
Expanded access 40
Unknown 1

How many Hemorrhagic Disorders trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 263
Recruiting 858
Enrolling by invitation 32
Active, not recruiting 413
Available 9

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Hemorrhagic Disorders trials? (8)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 192
Celgene 93
Novo Nordisk A/S 84
Pfizer 79
Janssen Research & Development, LLC 67

Showing 5 of 8 sponsors.

Start your 14-day trial Email me all 8 sponsors as a PDF

Which drugs are being tested for Hemorrhagic Disorders? (6)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 343
Melphalan 231
POMALIDOMIDE 186
RITUXIMAB 141
THALIDOMIDE 108

Showing 5 of 6 drugs.

Start your 14-day trial Email me all 6 drugs as a PDF

Interventions as named in the registry (9)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Dexamethasone/Dexamethasone acetate 759
Bortezomib SC 415
X: Lenalidomide 394
SQ Fludarabine 224
Daratumumab SC 205

Showing 5 of 9 interventions.

Start your 14-day trial Email me all 9 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Hemorrhagic Disorders trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 4,900 381
Pyrexia 1,730 262
Thrombocytopenia 1,562 231
Sepsis 1,341 333
Febrile neutropenia 1,319 252

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Hemorrhagic Disorders? (42)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Current Practice Regarding Bleeding Disorders of Unknown Cause in the Netherlands: A National Survey. Haemophilia : the official journal of the World Federation of Hemophilia 2025 Yes
tPA-ROTEM identifies hyperfibrinolytic profile in a significant proportion of patients with bleeding disorder of unknown cause (BDUC). Thrombosis research 2025 Yes
Harmonizing patient-reported outcome measurements in inherited bleeding disorders with PROMIS. Haemophilia : the official journal of the World Federation of Hemophilia 2023 Yes
The natural history of bleeding disorder of unknown cause. Journal of thrombosis and haemostasis : JTH 2023 Yes
Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021 Yes

Showing 5 of 42 publications.

Start your 14-day trial Email me all 42 publications as a PDF

Sub-conditions in MeSH (18)

MeSH descendants one level down with at least one trial, most trials first.

+8 more sub-conditions

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages